Невидимая угроза. Как Wi-Fi, сотовые телефоны, 5G и другие электромагнитные излучения влияют на наше самочувствие и продолжительность жизни

55. Fang EF, Lautrup S, Hou Y, Demarest TG, Croteau DL, Mattson MP, Bohr VA. “NAD(+) in Aging: Molecular Mechanisms and Translational Implications.” Trends in Molecular Medicine. Vol. 23, no. 10. (October 2017): 899–916. doi: 10.1016/j.molmed.2017.08.001.

56. Katsyuba E, Auwerx J. “Modulating NAD(+) Metabolism, from Bench to Bedside.” EMBO Journal. Vol. 36, no. 18. (September 15, 2017): 2670–2683. doi: 10.15252/embj.201797135.

57. Rajman L, Chwalek K, Sinclair DA. “Therapeutic Potential of NAD-Boosting Molecules: The in vivo Evidence.” Cellular Metabolism. Vol. 27, no. 3. (March 6, 2018): 529–547.

58. Yoshino J, Baur JA, Ima SI. “NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR.” Cellular Metabolism. Vol. 27, no. 3. (March 6, 2018): 513–528.

59. Grant RS, Kapoor V. “Murine Glial Cells Regenerate NAD, After Peroxide-Induced Depletion, Using Either Nicotinic Acid, Nicotinamide, or Quinolinic Acid as Substrates.” Journal of Neurochemistry. Vol. 70, no. 4. (April 1998): 1759–1763.

60. Elvehjem CA, Madden RJ, Strong FM, Woolley DW. “The Isolation and Identification of the Anti-Black Tongue Factor.” Nutrition Reviews. Vol. 32, no. 2. (February 1974): 48–50.

61. Mannar V, Hurrell R., editors. Food Fortification in a Globalized World. London: Academic Press/Elsevier, 2017.

62. Kirkland JB. “Niacin Status and Treatment-Related Leukemogenesis.” Molecular Cancer Therapeutics. Vol. 8, no. 4. (April 2009): 725–732.

63. Kirkland JB. “Niacin Status Impacts Chromatin Structure.” Journal of Nutrition. Vol. 139, no. 12. (December 2009): 2397–2401.

64. Kirkland JB. “Niacin Status and Genomic Instability in Bone Marrow Cells; Mechanisms Favoring the Progression of Leukemogenesis.” Subcellular Biochemistry. Vol. 56. (2012): 21–3.

65. Kirkland JB. “Niacin Requirements for Genomic Stability.” Mutation Research. Vol. 733, no. 1–2. (May 1, 2012): 14–20.

66. Menon RM, Gonzalez MA, Adams MH, Tolbert DS, Leu JH, Cefali EA. “Effect of the Rate of Niacin Administration on the Plasma and Urine Pharmacokinetics of Niacin and Its Metabolites.” Journal of Clinical Pharmacology. Vol. 47, no. 6. (June 2007): 681–768.

67. Peled T. “Nicotinamide, a SIRT1 Inhibitor, Inhibits Differentiation and Facilitates Expansion of Hematopoietic Progenitor Cells with Enhanced Bone Marrow Homing and Engraftment.” Experimental Hematology. Vol. 40, no. 4. (April 2012): 342–355.

68. Gaikwad A, Long DJ 2nd, Stringer JL, Jaiswal AK. “In Vivo Role of NAD(P)H: Quinone Oxidoreductase 1 (NQO1) in the Regulation of Intracellular Redox State and Accumulation of Abdominal Adipose Tissue.” Journal of Biological Chemistry. Vol. 276, no. 25. (June 22, 2001); 22559–25564.

69. Yaku K, Okabe K, Nakagawa T. “NAD Metabolism: Implications in Aging and Longevity.” Ageing Research Reviews. Vol. 47. (November 2018): 11–17. doi: 10.1016/j.arr.2018.05.006.

70. Müller F. “Flavin Radicals: Chemistry and Biochemistry.” Free Radical Biology and Medicine. Vol. 3, no. 3. (1987): 215–230.

71. Garber K. “Biochemistry: A Radical Treatment.” Nature. Vol. 489. (2012) S4–6.

72. Mathew ST, Bergström P, Hammarsten O. “Repeated Nrf2 Stimulation Using Sulforaphane Protects Fibroblasts from Ionizing Radiation.” Toxicology and Applied Pharmacology. Vol. 276, no. 3. (May 2014): 188–194.

73. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Sonis ST, Ward KW. “Topical Application of the Synthetic Triterpenoid RTA 408 Protects Mice from Radiation-Induced Dermatitis.” Radiation Research. Vol. 181, no. 5. (May 2014): 512–520.

74. Iranshahy M, Iranshahi M, Abtahi SR, Karimi G. “The Role of Nuclear Factor Erythroid 2-Related Factor 2 in Hepatoprotective Activity of Natural Products: A Review.” Food and Chemical Toxicology. Vol. 120. (October 2018): 261–276. doi: 10.1016/j.fct.2018.07.024.

75. O’Connell MA, Hayes JD. “The Keap1/Nrf2 Pathway in Health and Disease: From the Bench to the Clinic.” Biochemical Society Transactions. Vol. 43. (2015): 687–689.

76. Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. “Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study.” Chest. Vol. 151, no. 6. (June 2017): 1229–1238. doi: 10.1016/j.chest.2016.11.036.

77. Hershey TB, Kahn JM. “State Sepsis Mandates – A New Era for Regulation of Hospital Quality.” New England Journal of Medicine. Vol. 376, no. 24. (June 15, 2017): 2311–2313. doi: 10.1056/NEJMp1611928.